Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with zanubrutinib for relapsed or refractory primary central nervous system lymphoma
ChiCTR2100043653Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and zanubrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Shanxi Cancer Hospital. Primary endpoints: objective response rate and duration of response. Started Feb 2021; status: recruiting.
02
Drugs
camrelizumabzanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2100043653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043653.